Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 264

1.

Interim estimates of 2019/20 vaccine effectiveness during early-season co-circulation of influenza A and B viruses, Canada, February 2020.

Skowronski DM, Zou M, Sabaiduc S, Murti M, Olsha R, Dickinson JA, Gubbay JB, Croxen MA, Charest H, Jassem A, Krajden M, Bastien N, Li Y, De Serres G.

Euro Surveill. 2020 Feb;25(7). doi: 10.2807/1560-7917.ES.2020.25.7.2000103.

PMID:
32098644
2.

Quantification of the total neuraminidase content of recent commercially-available influenza vaccines: Introducing a neuraminidase titration reagent.

Gao Z, Robinson K, Skowronski DM, De Serres G, Withers SG.

Vaccine. 2020 Jan 22;38(4):715-718. doi: 10.1016/j.vaccine.2019.11.041. Epub 2019 Dec 7.

PMID:
31818533
3.

Paradoxical clade- and age-specific vaccine effectiveness during the 2018/19 influenza A(H3N2) epidemic in Canada: potential imprint-regulated effect of vaccine (I-REV).

Skowronski DM, Sabaiduc S, Leir S, Rose C, Zou M, Murti M, Dickinson JA, Olsha R, Gubbay JB, Croxen MA, Charest H, Bastien N, Li Y, Jassem A, Krajden M, De Serres G.

Euro Surveill. 2019 Nov;24(46). doi: 10.2807/1560-7917.ES.2019.24.46.1900585.

4.

Children vaccination coverage surveys: Impact of multiple sources of information and multiple contact attempts.

Kiely M, Boulianne N, Talbot D, Ouakki M, Guay M, Landry M, Sauvageau C, De Serres G.

Vaccine. 2020 Jan 29;38(5):1202-1210. doi: 10.1016/j.vaccine.2019.11.014. Epub 2019 Nov 21.

PMID:
31759736
5.

Impact of the adolescent pertussis booster dose on the incidence of pertussis in British Columbia and Quebec, Canada.

Brousseau N, Skowronski DM, Bellemare D, Amini R, Joffres Y, Clarke Q, Quach C, Rallu F, Hoang L, De Serres G.

Vaccine. 2020 Jan 16;38(3):427-432. doi: 10.1016/j.vaccine.2019.10.063. Epub 2019 Nov 1.

6.

Priming effect of bivalent and quadrivalent vaccine for HPV 31/33/45/52: an exploratory analysis from two clinical trials.

Sauvageau C, Panicker G, Unger ER, De Serres G, Schiller J, Ouakki M, Gilca V.

Hum Vaccin Immunother. 2019 Oct 22:1-5. doi: 10.1080/21645515.2019.1669413. [Epub ahead of print]

PMID:
31545130
7.

Letter to the editor: Measles outbreak in Gothenburg urban area, Sweden, 2017 to 2018: low viral load in breakthrough infections.

Bolotin S, Crowcroft NS, Hughes SL, De Serres G.

Euro Surveill. 2019 Jul;24(30). doi: 10.2807/1560-7917.ES.2019.24.30.1900465. No abstract available.

8.

A mixed vaccination schedule of HPV vaccine induces a 100% seropositivity to all 9 HPV types included in 9vHPV vaccine.

Gilca V, Sauvageau C, De Serres G.

Vaccine. 2019 Jul 26;37(32):4422-4423. doi: 10.1016/j.vaccine.2019.06.028. No abstract available.

PMID:
31319931
9.

Nephrotic syndrome following four-component meningococcal B vaccination: Epidemiologic investigation of a surveillance signal.

De Serres G, Billard MN, Gariépy MC, Roy MC, Boucher FD, Gagné H, Belley S, Toth E, Landry M, Skowronski DM.

Vaccine. 2019 Aug 14;37(35):4996-5002. doi: 10.1016/j.vaccine.2019.07.017. Epub 2019 Jul 12.

PMID:
31307873
10.

Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch.

Deceuninck G, Lefebvre B, Tsang R, Betala-Belinga JF, De Serres G, De Wals P.

Vaccine. 2019 Jul 18;37(31):4243-4245. doi: 10.1016/j.vaccine.2019.06.021. Epub 2019 Jun 22.

PMID:
31239214
12.

Evidence in a Cluster Randomized Controlled Trial of Increased 2009 Pandemic Risk Associated With 2008-2009 Seasonal Influenza Vaccine Receipt.

Skowronski DM, De Serres G.

Clin Infect Dis. 2019 Nov 27;69(12):2230-2231. doi: 10.1093/cid/ciz351. No abstract available.

13.

Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials.

Gilca V, Sauvageau C, Panicker G, De Serres G, Schiller J, Ouakki M, Unger ER.

Hum Vaccin Immunother. 2019;15(7-8):1980-1985. doi: 10.1080/21645515.2019.1605278. Epub 2019 Jun 3.

PMID:
31017850
14.

Children under 10 years of age were more affected by the 2018/19 influenza A(H1N1)pdm09 epidemic in Canada: ‎possible cohort effect following the 2009 influenza pandemic.

Skowronski DM, Leir S, De Serres G, Murti M, Dickinson JA, Winter AL, Olsha R, Croxen MA, Drews SJ, Charest H, Martineau C, Sabaiduc S, Bastien N, Li Y, Petric M, Jassem A, Krajden M, Gubbay JB.

Euro Surveill. 2019 Apr;24(15). doi: 10.2807/1560-7917.ES.2019.24.15.1900104.

15.

Rate of Recurrence of Adverse Events Following Immunization: Results of 19 Years of Surveillance In Quebec, Canada.

Zafack JG, Toth E, Landry M, Drolet JP, Top KA, De Serres G.

Pediatr Infect Dis J. 2019 Apr;38(4):377-383. doi: 10.1097/INF.0000000000002162.

PMID:
30882727
16.

Respiratory syncytial virus contributes to more severe respiratory morbidity than influenza in children < 2 years during seasonal influenza peaks.

Amini R, Gilca R, Boucher FD, Charest H, De Serres G.

Infection. 2019 Aug;47(4):595-601. doi: 10.1007/s15010-019-01287-5. Epub 2019 Feb 23.

PMID:
30798473
17.

Caution Required in the Use of Administrative Data and General Laboratory Submissions for Influenza Vaccine Effectiveness Estimation.

Skowronski DM, De Serres G, Orenstein WA.

Clin Infect Dis. 2019 Aug 30;69(6):1084-1085. doi: 10.1093/cid/ciz113. No abstract available.

18.

Interim estimates of 2018/19 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, January 2019.

Skowronski DM, Leir S, Sabaiduc S, Murti M, Dickinson JA, Olsha R, Gubbay JB, Croxen MA, Charest H, Chan T, Bastien N, Li Y, Krajden M, De Serres G.

Euro Surveill. 2019 Jan;24(4). doi: 10.2807/1560-7917.ES.2019.24.4.1900055.

19.

Assessment of naturally acquired neutralizing antibodies against rabies Lyssavirus in a subset of Nunavik's Inuit population considered most at risk of being exposed to rabid animals.

Ducrocq J, Proulx JF, Lévesque B, De Serres G, Wood H, Lemire M.

Zoonoses Public Health. 2019 Aug;66(5):533-539. doi: 10.1111/zph.12561. Epub 2019 Jan 27.

PMID:
30688040
20.

Impact of vaccine delays at the 2, 4, 6 and 12 month visits on incomplete vaccination status by 24 months of age in Quebec, Canada.

Kiely M, Boulianne N, Talbot D, Ouakki M, Guay M, Landry M, Sauvageau C, De Serres G.

BMC Public Health. 2018 Dec 11;18(1):1364. doi: 10.1186/s12889-018-6235-6.

21.

Application of the Test-Negative Design to General Laboratory Submissions.

Skowronski DM, De Serres G.

JAMA Pediatr. 2019 Feb 1;173(2):195-196. doi: 10.1001/jamapediatrics.2018.4370. No abstract available.

PMID:
30535171
22.

Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada.

De Serres G, Billard MN, Gariépy MC, Rouleau I, Toth E, Landry M, Boulianne N, Gagné H, Gilca V, Deceuninck G, Ouakki M, Skowronski DM.

Vaccine. 2018 Dec 18;36(52):8039-8046. doi: 10.1016/j.vaccine.2018.10.095. Epub 2018 Nov 19.

PMID:
30467063
23.

Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial.

Gilca V, Sauvageau C, Panicker G, De Serres G, Ouakki M, Unger ER.

Vaccine. 2018 Nov 12;36(46):7017-7024. doi: 10.1016/j.vaccine.2018.09.057. Epub 2018 Oct 9.

24.

Vaccine Effectiveness Against Lineage-matched and -mismatched Influenza B Viruses Across 8 Seasons in Canada, 2010-2011 to 2017-2018.

Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, Gubbay JB, Drews SJ, Fonseca K, Charest H, Martineau C, Hickman R, Chan T, Jassem A, Petric M, Rose C, Bastien N, Li Y, Krajden M.

Clin Infect Dis. 2019 May 2;68(10):1754-1757. doi: 10.1093/cid/ciy876.

25.

Investigation of an increase in large local reactions following vaccine schedule change to include DTaP-HB-IPV-Hib (Infanrix-hexa®) and MMRV (ProQuad®) at 18 months of age.

Kiely M, Billard MN, Toth E, Zafack JG, Landry M, Skowronski DM, De Serres G.

Vaccine. 2018 Oct 29;36(45):6688-6694. doi: 10.1016/j.vaccine.2018.09.049. Epub 2018 Sep 27.

PMID:
30269915
26.

Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later - an exploratory study.

Gilca V, Sauvageau C, Panicker G, De Serres G, Ouakki M, Unger ER.

Hum Vaccin Immunother. 2019;15(2):503-507. doi: 10.1080/21645515.2018.1522469. Epub 2018 Sep 27.

27.

Impact of the addition of new vaccines in the early childhood schedule on vaccine coverage by 24 months of age from 2006 to 2016 in Quebec, Canada.

Kiely M, Boulianne N, Talbot D, Ouakki M, Guay M, Landry M, Zafack J, Sauvageau C, De Serres G.

Vaccine. 2018 Jul 5;36(29):4383-4391. doi: 10.1016/j.vaccine.2018.03.085. Epub 2018 Jun 7.

PMID:
29887321
28.

Post-immunisation fever and the antibody response to measles-containing vaccines.

Carazo Perez S, Bureau A, De Serres G.

Epidemiol Infect. 2018 Sep;146(12):1584-1592. doi: 10.1017/S0950268818001474. Epub 2018 Jun 11.

PMID:
29886856
29.

Ecological Fallacy, Nonspecific Outcomes, and the Attribution of Disproportionate Vaccine Benefits.

De Serres G, Skowronski DM.

Clin Infect Dis. 2018 May 17;66(11):1817-1818. doi: 10.1093/cid/ciy014. No abstract available.

30.

Role of Egg-adaptation Mutations in Low Influenza A(H3N2) Vaccine Effectiveness During the 2012-2013 Season.

Skowronski DM, De Serres G.

Clin Infect Dis. 2018 Oct 15;67(9):1474-1476. doi: 10.1093/cid/ciy350. No abstract available.

31.

Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018.

Skowronski DM, Chambers C, De Serres G, Dickinson JA, Winter AL, Hickman R, Chan T, Jassem AN, Drews SJ, Charest H, Gubbay JB, Bastien N, Li Y, Krajden M.

Euro Surveill. 2018 Feb;23(5). doi: 10.2807/1560-7917.ES.2018.23.5.18-00035. Erratum in: Euro Surveill. 2018 Jul;23(30):.

32.

Delayed measles vaccination of toddlers in Canada: Associated socio-demographic factors and parental knowledge, attitudes and beliefs.

Périnet S, Kiely M, De Serres G, Gilbert NL.

Hum Vaccin Immunother. 2018 Apr 3;14(4):868-874. doi: 10.1080/21645515.2017.1412899. Epub 2018 Jan 16.

33.

Selection Bias in the Assessment of Frailty and Its Role in Influenza Vaccine Effectiveness Evaluation Among Elderly Adults.

Skowronski DM, Chambers C, De Serres G.

J Infect Dis. 2017 Dec 27;217(1):168. doi: 10.1093/infdis/jix548. No abstract available.

PMID:
29045721
34.

Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada.

Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, Gubbay JB, Drews SJ, Martineau C, Charest H, Krajden M, Bastien N, Li Y.

J Infect Dis. 2017 Dec 19;216(12):1487-1500. doi: 10.1093/infdis/jix526.

35.

Prevalence of risk factors for acquiring measles during the 2011 outbreak in Quebec and impact of the province-wide school-based vaccination campaign on population immunity.

Billard MN, De Serres G, Gariépy MC, Boulianne N, Toth E, Landry M, Skowronski DM.

PLoS One. 2017 Oct 11;12(10):e0186070. doi: 10.1371/journal.pone.0186070. eCollection 2017.

36.

Absence of association between Guillain-Barré syndrome hospitalizations and HPV-vaccine.

Deceuninck G, Sauvageau C, Gilca V, Boulianne N, De Serres G.

Expert Rev Vaccines. 2018 Jan;17(1):99-102. doi: 10.1080/14760584.2018.1388168. Epub 2017 Oct 13.

PMID:
28972438
37.

Age-Related Differences in Influenza B Infection by Lineage in a Community-Based Sentinel System, 2010-2011 to 2015-2016, Canada.

Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, Gubbay JB, Fonseca K, Drews SJ, Charest H, Martineau C, Krajden M, Petric M, Bastien N, Li Y.

J Infect Dis. 2017 Sep 15;216(6):697-702. doi: 10.1093/infdis/jix393.

38.

Risk of Recurrence of Adverse Events Following Immunization: A Systematic Review.

Zafack JG, De Serres G, Kiely M, Gariépy MC, Rouleau I, Top KA; Canadian Immunization Research Network .

Pediatrics. 2017 Sep;140(3). pii: e20163707. doi: 10.1542/peds.2016-3707. Review.

39.

Adverse events following live-attenuated intranasal influenza vaccination of children with cystic fibrosis: Results from two influenza seasons.

Boikos C, Joseph L, Scheifele D, Lands LC, De Serres G, Papenburg J, Winters N, Chilvers M, Quach C.

Vaccine. 2017 Sep 5;35(37):5019-5026. doi: 10.1016/j.vaccine.2017.07.068. Epub 2017 Jul 31.

PMID:
28774563
40.

Reply to Chung et al.

Skowronski DM, Chambers C, De Serres G.

J Infect Dis. 2017 Jul 15;216(2):285-287. doi: 10.1093/infdis/jix287. No abstract available.

PMID:
28633301
41.

Reduced Antibody Response to Infant Measles Vaccination: Effects Based on Type and Timing of the First Vaccine Dose Persist After the Second Dose.

Carazo Perez S, De Serres G, Bureau A, Skowronski DM.

Clin Infect Dis. 2017 Oct 1;65(7):1094-1102. doi: 10.1093/cid/cix510.

PMID:
28595358
42.

Repeated annual influenza vaccination and vaccine effectiveness: review of evidence.

Belongia EA, Skowronski DM, McLean HQ, Chambers C, Sundaram ME, De Serres G.

Expert Rev Vaccines. 2017 Jul;16(7):1-14. doi: 10.1080/14760584.2017.1334554. Epub 2017 Jun 9. Review. Erratum in: Expert Rev Vaccines. 2017 Aug;16(8):865-866.

PMID:
28562111
43.

RE: "DETECTABLE RISKS IN STUDIES OF THE FETAL BENEFITS OF MATERNAL INFLUENZA VACCINATION".

De Serres G, Skowronski DM.

Am J Epidemiol. 2017 May 1;185(9):860-861. doi: 10.1093/aje/kww202. No abstract available.

PMID:
28369245
44.

Knowledge, attitudes, beliefs, and behaviors of university students, faculty, and staff during a meningococcal serogroup B outbreak vaccination program.

MacDougall DM, Langley JM, Li L, Ye L, MacKinnon-Cameron D, Top KA, McNeil SA, Halperin BA, Swain A, Bettinger JA, Dubé E, De Serres G, Halperin SA; Canadian Immunization Research Network.

Vaccine. 2017 Apr 25;35(18):2520-2530. doi: 10.1016/j.vaccine.2017.02.011. Epub 2017 Mar 24.

PMID:
28347501
45.

Viral interference and the live-attenuated intranasal influenza vaccine: Results from a pediatric cohort with cystic fibrosis.

Boikos C, Papenburg J, Martineau C, Joseph L, Scheifele D, Chilvers M, Lands LC, De Serres G, Quach C.

Hum Vaccin Immunother. 2017 Jun 3;13(6):1-7. doi: 10.1080/21645515.2017.1287641. Epub 2017 Mar 8.

46.

Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada.

De Wals P, Deceuninck G, Lefebvre B, Tsang R, Law D, De Serres G, Gilca V, Gilca R, Boulianne N.

Clin Infect Dis. 2017 May 1;64(9):1263-1267. doi: 10.1093/cid/cix154.

PMID:
28207068
47.

Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017.

Skowronski DM, Chambers C, Sabaiduc S, Dickinson JA, Winter AL, De Serres G, Drews SJ, Jassem A, Gubbay JB, Charest H, Balshaw R, Bastien N, Li Y, Krajden M.

Euro Surveill. 2017 Feb 9;22(6). pii: 30460. doi: 10.2807/1560-7917.ES.2017.22.6.30460.

48.

Serial Vaccination and the Antigenic Distance Hypothesis: Effects on Influenza Vaccine Effectiveness During A(H3N2) Epidemics in Canada, 2010-2011 to 2014-2015.

Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, Gubbay JB, Fonseca K, Drews SJ, Charest H, Martineau C, Krajden M, Petric M, Bastien N, Li Y, Smith DJ.

J Infect Dis. 2017 Apr 1;215(7):1059-1099. doi: 10.1093/infdis/jix074.

49.

Influenza Vaccination of Healthcare Workers: Critical Analysis of the Evidence for Patient Benefit Underpinning Policies of Enforcement.

De Serres G, Skowronski DM, Ward BJ, Gardam M, Lemieux C, Yassi A, Patrick DM, Krajden M, Loeb M, Collignon P, Carrat F.

PLoS One. 2017 Jan 27;12(1):e0163586. doi: 10.1371/journal.pone.0163586. eCollection 2017.

50.

Clinical Approach Used in Medical Consultations for Allergic-Like Events Following Immunization: Case Series Report in Relation to Practice Guidelines.

Zafack JG, De Serres G, Rouleau I, Gariépy MC, Gagnon R, Drolet JP, Skowronski DM.

J Allergy Clin Immunol Pract. 2017 May - Jun;5(3):718-727.e1. doi: 10.1016/j.jaip.2016.09.048. Epub 2016 Nov 30.

PMID:
27914816

Supplemental Content

Loading ...
Support Center